|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The hyaluronidase market is expected to register a CAGR of 8.5% during the forecast period.
COVID-19 had a significant impact on the market during the pandemic period. As per the Aesthetic Surgery Journal in July 2020, in the United States, the total surgeons' fee derived from both surgical and minimally invasive procedures in 2018 was approximately USD 5 billion. The pandemic resulted in an approximately 20% decrease in collected fees, which negatively impacted the market in 2020. Hence, the negative impact was observed in the initial phase of pandemic due to shut down of the elective procedures. However, factors such as rising awareness about the change in physical appearance have led to the increasing demand for cosmetics and aesthetic procedures and thereby observe the positive impact from the end of the pandemic. According to an article by the Acquisition Aesthetics in December 2021, the demand for aesthetic procedures saw a steady rise in the United Kingdom, during the pandemic, even when the clinics were closed since the consumers were focused on spending more on aesthetic treatments, once the restrictions were eased. The article also established that the pandemic had paved the way for video conferencing platforms as a means of communication by the United Kingdom workforce. Such digital technology platforms had increased the amount of time spent by consumers looking at themselves for a longer period. This increase has had a significant impact on consumer views about aesthetics and had invariably added to the growth of the market.
The demand for hyaluronidase in cosmetic dermatology is increasingly driven by the rise in the prevalence of skin disorders and easy access to advanced cosmetic treatments. Also, the increasing adoption of hyaluronidase in the cosmetic procedures are expected to drive the growth of the market. According to the American Society of Plastic Surgeons report 2020, there were about 2,619,650 procedures incoving hyalurnic acid in socmetic surgeries. Moreover, rising penetration across various application areas and the presence of several clinical studies to determine the efficacy of the products are driving the hyaluronidase market. Moreover, the use of enzyme-based substrate for noninvasive tumor imaging in cancer metastasis, numerous applications in cancer therapy, cosmetic treatments, and ophthalmic therapeutic solutions are also key driving factors in the market. Furthermore, a rise in the number of people opting for aesthetic non-surgical procedures, a rising geriatric population, and favorable reimbursement policies are also expected to fuel the hyaluronidase market. However, Adverse effects associated with hyaluronidases like skin rashes, and unusual weakness may hamper the market growth.
Scope of the Report
As per the scope of the report, hyaluronidase are enzymes that catalyze the degradation of hyaluronic acid and enhanced permeability of connective tissues. These enzymes are widely used in aesthetic procedures. The Hyaluronidase market is segmented By Type (Animal-derived Hyaluronidase, Synthetic Hyaluronidase), By Application (Chemotherapy, Invitro Fertilization, Ophthalmology, Dermatology and Others) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
|In Vitro Fertilization|
|Others (Plastic surgery)|
Key Market Trends
Animal-derived hyaluronidase Segment is Expected to Contribute a Major Market Share in the Hyaluronidase Market
Animal-derived hyaluronidase is contributing to high market share attributing to most of the approved and commercialized brands being derived from animal sources only. Bovine and porcine are some of the widely used animal sources. Hydase (PrimaPharma), Vitrase (Bausch &Lomb Incorporated), and Amphadase(Amphastar Pharmaceuticals, Inc.) are some of the brands manufactured by manufacturers. Moreover, The animal-derived hyaluronidase market has witnessed a substantial number of product approvals leading to promoting the growth of the market. For instance, in March 2019, Genentech received FDA approval for Herceptin hylecta which is a subcutaneous injection in which intravenous Herceptin (trastuzumab) and recombinant human hyaluronidase PH20 enzyme help to deliver trastuzumab to the skin for the treatment of breast cancer patients, hence the market is expected to witness healthy CAGR over the forecast period.
Also, the benefits of animal-derived hyaluronidase over the other types are expected to contribute to the growth of the studied segment. According to the article titled " Safety of recombinant human hyaluronidase PH20 for subcutaneous drug deliver" published in April 2020 animal-derived hyaluronidases have been used for more than 70 years to modify tissue permeability through depolymerization of Hyaluronic acid and to increase the dispersion of other infused drugs.
Thus the above-mentioned factors are expected to drive the growth of the studied segment during the forecast period.
To understand key trends, Download Sample Report
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America expected to hold a major market share in the global hyaluronidase market due to the presence of major players manufacturing these products, high adoption of advanced treatment options and a substantial number of dermatology clinics prescribing such treatments. Moreover, increasing healthcare expenditure and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.
Also, the increasing adoption of comstic procedures in United States is also expected to drive the demand for the market. For instance accordingto the American Society for Plastic Surgeons 2020 report, the number of hyaluronic acid cosmetic procedures in United States in both genders were 2,619,650. Such adoption of comsteic procedues in United States is expected to drive the growth of the market in the forecast period.
To understand geography trends, Download Sample Report
The hyaluronidase market is fragmented, competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are PrimaPharma, Inc, Amphastar Pharmaceuticals, Inc., Bausch & Lomb Incorporated, Halozyme, Inc., Sun Pharmaceutical Industries Ltd, STEMCELL Technologies, Inc. and CooperSurgical Fertility and Genomic Solutions.
Amphastar Pharmaceuticals, Inc
Bausch & Lomb Incorporated
Sun Pharmaceutical Industries Ltd
- In July 2022 Takeda announced positive topline results from the phase 3 clinical trial evaluating HYQIA (immune globulin infusion 10%(human) with recombinant human hyaluronidase) for maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy.
- In August 2021, Mesoestectic launched a range of moisturizing solutions in which the product contains hyaluronic acid for hydration application.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Penetration of Hyaluronidase in Correction Procedures
4.2.2 Rising Demand for Minimally Invasive Aesthetic Treatments
4.3 Market Restraints
4.3.1 Adverse Effects associated with Hyaluronidases
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Type
5.1.1 Animal-derived Hyaluronidase
5.1.2 Synthetic Hyaluronidase
5.2 By Application
5.2.2 In Vitro Fertilization
5.2.5 Others (Plastic surgery)
5.3.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.3.4 Middle East and Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle East and Africa
5.3.5 South America
126.96.36.199 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 PrimaPharma, Inc
6.1.2 Amphastar Pharmaceuticals, Inc.
6.1.3 Bausch & Lomb Incorporated
6.1.4 Halozyme, Inc.
6.1.5 Sun Pharmaceutical Industries Ltd
6.1.6 STEMCELL Technologies, Inc.
6.1.7 The Cooper Companies, Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Frequently Asked Questions
What is the study period of this market?
The Global Hyaluronidase Market market is studied from 2019 - 2027.
What is the growth rate of Global Hyaluronidase Market?
The Global Hyaluronidase Market is growing at a CAGR of 8.5% over the next 5 years.
Which region has highest growth rate in Global Hyaluronidase Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Hyaluronidase Market?
North America holds highest share in 2021.
Who are the key players in Global Hyaluronidase Market?
PrimaPharma, Inc, Amphastar Pharmaceuticals, Inc, Bausch & Lomb Incorporated, Halozyme, Inc., Sun Pharmaceutical Industries Ltd are the major companies operating in Global Hyaluronidase Market.